title: Reappraisal of the prostaglandin E1 dose for early newborns with patent ductus arteriosus-dependent pulmonary circulation.
abstract: OBJECTIVE
  The usual initial dose of prostaglandin E1 (PGE1) for ductal-dependent congenital heart disease (CHD) is 50-100 ng/kg/minute. The aim of this study was to review our experience of a low initial dose of PGE1 treatment in early newborns with congenital heart disease and patent ductus arteriosus (PDA)-dependent pulmonary flow.
  
  
  METHODS
  We reviewed the clinical data of 33 newborns with CHD and PDA-dependent pulmonary circulation who were admitted from January 2005 to December 2010. Clinical parameters were collected, including, PGE1 dosage, oxygenation condition, vital signs, and other related clinical parameters during admission. Echocardiography was employed to assess the status of the PDA as clinically indicated.
  
  
  RESULTS
  Thirty-three newborns, including 17 males and 16 females, with CHD and PDA-dependent pulmonary circulation were enrolled in the study. Their mean age was 2.9 ± 5.1 (within the range of 1-26) days with a median of 1.0 day. Among the 33 cases, 25 were diagnosed with pulmonary atresia and eight with critical pulmonary stenosis. Twenty-five of our patients were treated with the initial low-dosage regimen of 20.0 ± 7.4 ng/kg/minute in our neonatal intensive care unit. None of these 25 patients with had significant apnea necessitating intubation and none had hypotension, fever, convulsion or cortical hyperostosis. Three of the eight patients who were treated with high-dose PGE1 (39 ± 13.2 ng/kg/minute) before referral to our unit had apnea and intubation after PGE1 use. All patients had adequate PDA patency with a low maintenance dose of 10.5 ± 5.3 ng/kg/minute before operation under our protocol.
  
  
  CONCLUSIONS
  In our experience, adequate PDA flows in early newborns with CHD and PDA-dependent pulmonary circulation could be achieved at a much lower dose than recommended in the literature. The lower dose of PGE1 also causes much fewer complications, such as apnea, fever, and hypotension. For early newborns with CHD and PDA-dependent pulmonary circulation, treatment with a lower initial dose of PGE1 of 20 ng/kg/minute and a maintenance dose of 10 ng/kg/minute is recommended.
authors.affiliation: Department of Pediatrics, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC.
authors.forename: Fu-Kuei
authors.initials: FK
authors.lastname: Huang
authors.forename: Chu-Chuan
authors.initials: CC
authors.lastname: Lin
authors.forename: Ta-Cheng
authors.initials: TC
authors.lastname: Huang
authors.forename: Ken-Pen
authors.initials: KP
authors.lastname: Weng
authors.forename: Po-Yen
authors.initials: PY
authors.lastname: Liu
authors.forename: Ying-Yao
authors.initials: YY
authors.lastname: Chen
authors.forename: Hsiao-Ping
authors.initials: HP
authors.lastname: Wang
authors.forename: Luo-Ping
authors.initials: LP
authors.lastname: Ger
authors.forename: Kai-Sheng
authors.initials: KS
authors.lastname: Hsieh
mesh_terms: D000527:Alprostadil / Q000008:administration & dosage*; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy*; D005260:Female; D006330:Heart Defects, Congenital / Q000503:physiopathology*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D011652:Pulmonary Circulation
chemical_list: D000527:Alprostadil